An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial
Top Cited Papers
- 4 July 2008
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 372 (9633) , 145-154
- https://doi.org/10.1016/s0140-6736(08)60697-2
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Tumor Size Predicts Synchronous Metastatic Renal Cell Carcinoma: Implications for Surveillance of Small Renal MassesJournal of Urology, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Staging of renal cell carcinoma: current conceptsBJU International, 2005
- Phase III Study of Interferon Alfa-NL as Adjuvant Treatment for Resectable Renal Cell Carcinoma: An Eastern Cooperative Oncology Group/Intergroup TrialJournal of Clinical Oncology, 2003
- Risk Group Assessment and Clinical Outcome Algorithm to Predict the Natural History of Patients With Surgically Resected Renal Cell CarcinomaJournal of Clinical Oncology, 2002
- Interferon Adjuvant to Radical Nephrectomy in Robson Stages II and III Renal Cell Carcinoma: A Multicentric Randomized StudyJournal of Clinical Oncology, 2001
- PROGNOSTIC INDICATORS FOR RENAL CELL CARCINOMA: A MULTIVARIATE ANALYSIS OF 643 PATIENTS USING THE REVISED 1997 TNM STAGING CRITERIAJournal of Urology, 2000
- Role of lymphadenectomy in the treatment of renal cell carcinomaUrology, 1993
- What are the Benefits of Extended Dissection of the Regional Renal Lymph Nodes in the Therapy of Renal Cell Carcinoma?Journal of Urology, 1991
- Radical Extensive Surgery for Renal Cell Carcinoma: Long-Term Results and Prognostic FactorsJournal of Urology, 1990